The "Subsidy scheme for promising care" framework aims to speed up the patient's access to potentially promising care through temporary inclusion in the basic insurance package. A maximum of €69 million is available annually.
On July 13, 2021, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced the projects which were awarded the "Subsidy scheme for promising care". Two of them concern MedTech and are listed below:
- Automatic regulation of blood glucose in type 1 diabetes: effectiveness of the artificial pancreas
- Knee distraction compared with knee prosthesis for patients with severe knee osteoarthritis who respond insufficiently to conservative treatments
Based on the scientific evidence, the ZIN will take a position within six months after the end of the research process to determine whether these services meet "the current state of science and practice". If the effectiveness is proved, the treatment will be reimbursed under basic insurance.
The full details in Dutch can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).